Press release
Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review | Evaxion Biotech, Nouscom, Amgen, Dendreon Pharma, IO Biotech
"Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neoantigen Based Personalized Cancer Therapeutic Vaccines Market.
The Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Neoantigen Based Personalized Cancer Therapeutic Vaccines treatment therapies with a considerable amount of success over the years.
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines companies working in the treatment market are Evaxion Biotech, Nouscom, Amgen, Dendreon Pharmaceuticals, IO Biotech, Candel Therapeutics, Merck/Moderna, Geneos Therapeutics, Enterome, Johnson & Johnson, and others, are developing therapies for the Neoantigen Based Personalized Cancer Therapeutic Vaccines treatment
*
Emerging Neoantigen Based Personalized Cancer Therapeutic Vaccines therapies in the different phases of clinical trials are- EVX-01, NOUS-PEV, IMLYGIC (talimogene laherparepvec), PROVENGE (sipuleucel-T), IO102-IO103, CAN-2409, mRNA-4157 (V940) + KEYTRUDA, GNOS-PV02, EO2401, VAC85135, and others are expected to have a significant impact on the Neoantigen Based Personalized Cancer Therapeutic Vaccines market in the coming years.
*
In December 2024, NEC Bio Therapeutics unveiled promising 24-week interim results from its ongoing Phase 1 basket trial evaluating NECVAX-NEO1, an orally administered cancer vaccine, in combination with checkpoint inhibitors (CPI) for treating solid tumors. NECVAX-NEO1 is a personalized, bacteria-based oral DNA therapeutic vaccine developed using AI-driven prediction of patient-specific neoepitopes. Designed to stimulate the immune system, the vaccine triggers a T-cell response that precisely targets and eliminates tumor cells based on an individual's unique neoantigens.
*
In April 2024, Geneos Therapeutics reported positive Phase I/II results from the GT-30 trial evaluating GNOS-PV02 for advanced hepatocellular carcinoma, with select clinical trial findings also presented at the 2024 AACR Annual Meeting.
*
According to the April 2024 presentation, IO Biotech's Phase III pivotal trial of IO102-IO103 has completed enrollment, with progression-free survival (PFS) as the primary endpoint. An interim analysis is anticipated in Q3 2024, and if the results are favorable, the therapy could receive accelerated approval in 2025.
Neoantigen Based Personalized Cancer Therapeutic Vaccines Overview
Neoantigen-based personalized cancer therapeutic vaccines are a type of immunotherapy designed to stimulate the immune system to recognize and attack cancer cells. These vaccines are tailored to individual patients based on tumor-specific neoantigens, which are unique mutated proteins found in cancer cells but not in normal tissues.
Get a Free Sample PDF Report to know more about Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-insight [https://www.delveinsight.com/report-store/neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Neoantigen Based Personalized Cancer Therapeutic Vaccines Drugs Under Different Phases of Clinical Development Include:
*
EVX-01: Evaxion Biotech
*
NOUS-PEV: Nouscom
*
IMLYGIC (talimogene laherparepvec): Amgen
*
PROVENGE (sipuleucel-T): Dendreon Pharmaceuticals
*
IO102-IO103: IO Biotech
*
CAN-2409: Candel Therapeutics
*
mRNA-4157 (V940) + KEYTRUDA: Merck/Moderna
*
GNOS-PV02: Geneos Therapeutics
*
EO2401: Enterome
*
VAC85135: Johnson & Johnson
Neoantigen Based Personalized Cancer Therapeutic Vaccines Route of Administration
Neoantigen Based Personalized Cancer Therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Neoantigen Based Personalized Cancer Therapeutic Vaccines Molecule Type
Neoantigen Based Personalized Cancer Therapeutic Vaccines Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Therapeutics Assessment
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines Assessment by Product Type
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines By Stage and Product Type
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines Assessment by Route of Administration
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines By Stage and Route of Administration
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines Assessment by Molecule Type
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines by Stage and Molecule Type
DelveInsight's Neoantigen Based Personalized Cancer Therapeutic Vaccines Report covers around 15+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Neoantigen Based Personalized Cancer Therapeutic Vaccines product details are provided in the report. Download the Neoantigen Based Personalized Cancer Therapeutic Vaccines pipeline report to learn more about the emerging Neoantigen Based Personalized Cancer Therapeutic Vaccines therapies [https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapeutics Market include:
Key companies developing therapies for Neoantigen Based Personalized Cancer Therapeutic Vaccines are - BioNTech, Genentech, Moderna, Merck & Co., Gritstone bio, Evaxion Biotech, and others.
Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Analysis:
The Neoantigen Based Personalized Cancer Therapeutic Vaccines pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Neoantigen Based Personalized Cancer Therapeutic Vaccines with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neoantigen Based Personalized Cancer Therapeutic Vaccines Treatment
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neoantigen Based Personalized Cancer Therapeutic Vaccines market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Neoantigen Based Personalized Cancer Therapeutic Vaccines drugs and therapies [https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Market Drivers
*
Advancements in Genomic Sequencing, Growing Demand for Personalized Medicine, Rising Cancer Incidence, Increased Research & Development Funding, Combination Therapies with Immunotherapies, Regulatory Support & Fast-Track Approvals, are some of the important factors that are fueling the Neoantigen Based Personalized Cancer Therapeutic Vaccines Market.
Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Market Barriers
*
However, High Development Costs, Complex Manufacturing Process, Regulatory & Approval Hurdles, Limited Clinical Data, Patient-Specific Variability, Infrastructure & Accessibility Issues, and other factors are creating obstacles in the Neoantigen Based Personalized Cancer Therapeutic Vaccines Market growth.
Scope of Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Drug Insight
*
Coverage: Global
*
Key Neoantigen Based Personalized Cancer Therapeutic Vaccines Companies: Evaxion Biotech, Nouscom, Amgen, Dendreon Pharmaceuticals, IO Biotech, Candel Therapeutics, Merck/Moderna, Geneos Therapeutics, Enterome, Johnson & Johnson, and others
*
Key Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapies: EVX-01, NOUS-PEV, IMLYGIC (talimogene laherparepvec), PROVENGE (sipuleucel-T), IO102-IO103, CAN-2409, mRNA-4157 (V940) + KEYTRUDA, GNOS-PV02, EO2401, VAC85135, and others
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapeutic Assessment: Neoantigen Based Personalized Cancer Therapeutic Vaccines current marketed and Neoantigen Based Personalized Cancer Therapeutic Vaccines emerging therapies
*
Neoantigen Based Personalized Cancer Therapeutic Vaccines Market Dynamics: Neoantigen Based Personalized Cancer Therapeutic Vaccines market drivers and Neoantigen Based Personalized Cancer Therapeutic Vaccines market barriers
Request for Sample PDF Report for Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Neoantigen Based Personalized Cancer Therapeutic Vaccines Report Introduction
2. Neoantigen Based Personalized Cancer Therapeutic Vaccines Executive Summary
3. Neoantigen Based Personalized Cancer Therapeutic Vaccines Overview
4. Neoantigen Based Personalized Cancer Therapeutic Vaccines- Analytical Perspective In-depth Commercial Assessment
5. Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline Therapeutics
6. Neoantigen Based Personalized Cancer Therapeutic Vaccines Late Stage Products (Phase II/III)
7. Neoantigen Based Personalized Cancer Therapeutic Vaccines Mid Stage Products (Phase II)
8. Neoantigen Based Personalized Cancer Therapeutic Vaccines Early Stage Products (Phase I)
9. Neoantigen Based Personalized Cancer Therapeutic Vaccines Preclinical Stage Products
10. Neoantigen Based Personalized Cancer Therapeutic Vaccines Therapeutics Assessment
11. Neoantigen Based Personalized Cancer Therapeutic Vaccines Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Neoantigen Based Personalized Cancer Therapeutic Vaccines Key Companies
14. Neoantigen Based Personalized Cancer Therapeutic Vaccines Key Products
15. Neoantigen Based Personalized Cancer Therapeutic Vaccines Unmet Needs
16 . Neoantigen Based Personalized Cancer Therapeutic Vaccines Market Drivers and Barriers
17. Neoantigen Based Personalized Cancer Therapeutic Vaccines Future Perspectives and Conclusion
18. Neoantigen Based Personalized Cancer Therapeutic Vaccines Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neoantigen-based-personalized-cancer-therapeutic-vaccines-pipeline-2024-detailed-clinical-trials-and-fdaapproved-therapies-review-evaxion-biotech-nouscom-amgen-dendreon-pharma-io-biotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neoantigen Based Personalized Cancer Therapeutic Vaccines Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review | Evaxion Biotech, Nouscom, Amgen, Dendreon Pharma, IO Biotech here
News-ID: 3857196 • Views: …
More Releases from ABNewswire
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
The Debut Album of Soldier'z of the Most High (S.O.T.M.H): The City in the Sky N …
From sourthern roots and legendary encounters to a new sound called Salvation Music, Chattanooga's own Freddy Mac delivers his long-awaited debut album.
Chattanooga, TN - The wait is over. Freddy Mac 2025 and his band Soldier'z of the Most High (S.O.T.M.H) proudly unveil their long-anticipated debut album, The City in the Sky. This groundbreaking project introduces Salvation Music [http://www.salvationmusic.com], a bold fusion of funk, metal, soul, and classical influences, brought to…
Author's Tranquility Press Announces the Heartwarming Release of Lil' Hal's Gian …
A Christmas Tale of Wonder, Patience, and Family Love That Shines Beyond the Wrapping Paper
Few things capture the spirit of Christmas like the thrill of a child discovering a gift under the tree. In Lil' Hal's Giant Christmas Box [https://www.amazon.com/Lil-Hals-Giant-Christmas-Box/dp/195754662X/ref=monarch_sidesheet_title] by Christy B., readers are invited into a magical holiday morning filled with suspense, laughter, and an unforgettable lesson: sometimes the greatest gifts require patience, faith, and love.
This beautifully illustrated…
"The Expedia of VoIP": Business Phone System Disrupts Carrier Model with Transpa …
Business owners can now shop multiple providers at once-choosing the right system without sales pressure or hidden fees.
Sheridan, Wyoming - Business Phone System, a vendor-neutral platform for business communications, today announced its official launch, offering business owners a smarter way to evaluate and select telecom services. Unlike traditional carriers that push their own packages, Business Phone System enables organizations to compare multiple providers side-by-side, ensuring the right solution is sized…
More Releases for Therapeutic
Exosome Therapeutic Market : Detailed Overview
Introduction:
The exosome therapeutic market is a rapidly emerging segment in the field of regenerative medicine and drug delivery. Exosomes are extracellular vesicles naturally released by cells that play a crucial role in cell communication and genetic material transfer. They have gained attention for their potential applications in treating various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. As a novel therapeutic platform, exosomes provide significant advantages such as low immunogenicity,…
Parkinson's Disease Therapeutic Market Hope for Patients: The Parkinson's Diseas …
Parkinson's Disease Therapeutic Market worth $6.51 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Parkinson's Disease Therapeutic Market - (By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand (Branded, Generics), By Route of Administration (Oral, Injectable, Intestinal Infusion, Subcutaneous, Others)),…
Global Remote Therapeutic Monitoring Market
According to a new market research report published by Global Market Estimates, the Global Remote Therapeutic Monitoring Market is projected to grow at a CAGR of 17.4% from 2023 to 2028.
Medsien, Intellihinc, Zimmer Biomet, Owlytics Healthcare, Limber Health, Medistics, RxCap, Propeller Health, HealthArc, CENSON Health, and B Castle Smith & Co., are some of the key players in the remote therapeutic monitoring market.
Browse 147 Market Data Tables and 115…
Europe Digital Therapeutic (DTx) Market
Europe Digital Therapeutic (DTx) Market report provides information about the industry, including valuable Analysis and Detailed study. This research study explores the Global Europe Digital Therapeutic (DTx) Market in detail such as industry chain structures, raw material suppliers, with manufacturing. The Europe Digital Therapeutic (DTx) market examines the primary segments of the market. This intelligent study provides historical data from forecast.It also provides the details such as whether the customers…
Recombinant Therapeutic Antibodies and Proteins Market continues to expand with …
Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies…
Therapeutic Vaccine Market 2020 - 2028 Top Companies Agenus Inc., Argos Therapeu …
This detailed market study covers therapeutic vaccine market growth potentials which can assist the stake holders to understand key trends and prospects in therapeutic vaccine market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The…
